Nanoligent Analysis
What is Nanoligent?
Precision medicines through advanced nanobiotechnology
Founded
2017
Industry
Biotechnology
Interests
Artificial Intelligence, Big Data/Analytics, Health/Fitness/Wellbeing, Manufacturing and Industry 4.0
Startup Tag
Yes
Product Features & Capabilities
- Targeted drug therapy using protein engineering
- Development of protein conjugates for specific biological systems
- Advanced drug delivery systems for oncology
- Research publications in biomedicine
- Collaboration with academic and medical institutions.
Use Cases
Develop targeted cancer therapies for improved patient outcomes; Engineer protein conjugates for precise drug delivery; Conduct research to advance biomedicine knowledge; Collaborate with partners for innovative therapeutic solutions; Create affordable cancer treatments with high social impact.
Other Considerations
Founded in 2017 by experts in nanobiotechnology; Spin-off from Universitat Autònoma de Barcelona and Institut de Recerca de l’Hospital de la Santa Creu I Sant Pau; Funded by the European Union – NextGenerationEU.
4 Yfn Page Information
Main Information
- Information: Nanoligent is a preclinical-stage biotech company based in Barcelona, focused on developing precision nanomedicines designed to selectively target and eliminate tumor cells that overexpress the CXCR4 receptor. The company is currently raising capital to advance its lead candidate into clinical trials.
- Interests: Artificial Intelligence, Big Data/Analytics, Health/Fitness/Wellbeing, Manufacturing and Industry 4.0.
- Location: Hall 8.1 - 4YFN Stand 8.1C42.5.
- Whether tagged as startup: Yes, Nanoligent is tagged as a startup.
- LinkedIn: Connect on LinkedIn
- Twitter: Not available.
- Phone Number: Not available.
- Email: Email (link to email).
- Growth Stage: Series A.
- Country: Spain.
- Founding Year: 2017.
- Company Name: Nanoligent
- Company Website: https://www.nanoligent.com/
